Immunicom Secures Additional $1.85M Bringing Series B to $12.85M

immunicomImmunicom, Inc., a San Diego, CA-based medical technology company providing a non-pharmaceutical solution for treating stage IV metastatic cancer, raised an additional $1.85m towards its Series B investment round.

This increases Series B round to $12.85m investment round and overall capital raised to $21.85m.

Led by Amir Jafri, Founder and CEO, Immunicom is a medical technology company focused on developing innovative, non-pharmaceutical approaches for treating cancer, inflammatory diseases, and autoimmune diseases. Its blood-filtering technology has the potential to effectively treat a wide variety of cancer types including those that have not responded to other treatment strategies including other drug and biological-based immunotherapy options with possibly fewer side effects.

The company has also hired Raju Chauhan as Vice President of Program Management to provide guidance and oversight to both internal and customer facing initiatives.
Raju has over 30 years of experience working in the technology development and managing teams across the globe with a proven record of creating and delivering, innovative, cost-effective solutions for mission-critical business problems. He has been an integral part of managing projects for several fortune 50 companies as well as healthcare space. At Cardinal Health, Raju managed teams spread across several locations in USA. Raju has also managed and worked with many different teams in several countries including Canada, China, India, and Ukraine. He has worked in many different industries including Medical Device Manufacturers, Healthcare, Oil and Gas, Software, Telecommunications, Food and Beverages, Airlines, Credit Bureaus, Background Checks, Real Estate, Professional Services and Utilities.
Raju received his Master of Computer Science degree from Mississippi State University.

FinSMEs

01/10/2019

Join the discussion